WO2002086100A3 - Expression of core-glycosylated hcv envelope proteins in yeast - Google Patents
Expression of core-glycosylated hcv envelope proteins in yeast Download PDFInfo
- Publication number
- WO2002086100A3 WO2002086100A3 PCT/BE2002/000063 BE0200063W WO02086100A3 WO 2002086100 A3 WO2002086100 A3 WO 2002086100A3 BE 0200063 W BE0200063 W BE 0200063W WO 02086100 A3 WO02086100 A3 WO 02086100A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- envelope proteins
- yeast
- core
- expression
- hcv envelope
- Prior art date
Links
- 101710091045 Envelope protein Proteins 0.000 title abstract 3
- 101710188315 Protein X Proteins 0.000 title abstract 3
- 102100021696 Syncytin-1 Human genes 0.000 title abstract 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract 1
- 241000235648 Pichia Species 0.000 abstract 1
- 241000235070 Saccharomyces Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24223—Virus like particles [VLP]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002583615A JP4261195B2 (en) | 2001-04-24 | 2002-04-24 | Expression of yeast core-glycosylated HCV envelope proteins |
CA002444006A CA2444006A1 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
AU2002252856A AU2002252856A1 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
EP02721875A EP1414942A2 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01870088 | 2001-04-24 | ||
EP01870088.0 | 2001-04-24 | ||
US30560401P | 2001-07-17 | 2001-07-17 | |
US60/305,604 | 2001-07-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002086100A2 WO2002086100A2 (en) | 2002-10-31 |
WO2002086100A3 true WO2002086100A3 (en) | 2004-02-19 |
Family
ID=34072546
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2002/000063 WO2002086100A2 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
PCT/BE2002/000062 WO2002085932A2 (en) | 2001-04-24 | 2002-04-24 | Constructs and methods for expression of recombinant hcv envelope proteins |
PCT/BE2002/000064 WO2002086101A2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2002/000062 WO2002085932A2 (en) | 2001-04-24 | 2002-04-24 | Constructs and methods for expression of recombinant hcv envelope proteins |
PCT/BE2002/000064 WO2002086101A2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
Country Status (20)
Country | Link |
---|---|
US (3) | US7238356B2 (en) |
EP (3) | EP1414942A2 (en) |
JP (2) | JP4261195B2 (en) |
KR (1) | KR100950104B1 (en) |
CN (1) | CN1636050A (en) |
AR (3) | AR035869A1 (en) |
AU (3) | AU2002308449B2 (en) |
BR (2) | BR0209034A (en) |
CA (3) | CA2443781A1 (en) |
CZ (1) | CZ20032853A3 (en) |
HU (1) | HUP0303924A2 (en) |
MX (2) | MXPA03009626A (en) |
NZ (2) | NZ529324A (en) |
OA (1) | OA13092A (en) |
PL (1) | PL366621A1 (en) |
RU (1) | RU2274643C2 (en) |
SK (1) | SK13142003A3 (en) |
WO (3) | WO2002086100A2 (en) |
YU (1) | YU84103A (en) |
ZA (3) | ZA200308272B (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040185061A1 (en) * | 1994-07-29 | 2004-09-23 | Innogenetics N.V. | Redox reversible HCV proteins with native-like conformation |
EP1414942A2 (en) * | 2001-04-24 | 2004-05-06 | Innogenetics N.V. | Expression of core-glycosylated hcv envelope proteins in yeast |
DE10143490C2 (en) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Recombinant MVA with the ability to express HCV structural antigens |
CA2504711A1 (en) * | 2002-11-08 | 2004-05-21 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
JP4371739B2 (en) * | 2003-09-02 | 2009-11-25 | 株式会社東芝 | Electronic device having serial ATA interface and power saving method of serial ATA bus |
EP1602664A1 (en) * | 2004-03-08 | 2005-12-07 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
EP1574517A1 (en) | 2004-03-09 | 2005-09-14 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
JP4885476B2 (en) * | 2004-05-21 | 2012-02-29 | 株式会社日本触媒 | Method for introducing protein and / or peptide into cell |
SG156652A1 (en) * | 2004-10-18 | 2009-11-26 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis c infection |
AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US20060234360A1 (en) * | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
PE20070796A1 (en) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS |
WO2007136865A2 (en) * | 2006-05-19 | 2007-11-29 | Glycofi, Inc | Recombinant vectors |
AU2015234338C1 (en) * | 2006-07-28 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
CN101563362B (en) * | 2006-08-25 | 2015-02-11 | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | Recombinant HCV E2 glycoprotein |
US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
DE102009044224A1 (en) * | 2009-10-09 | 2011-04-28 | PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 | Method for production of HCV virus-like particles |
UA118537C2 (en) | 2010-12-22 | 2019-02-11 | Байєр Інтеллектуал Проперті Гмбх | Enhanced immune response in bovine species |
US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
WO2012152823A1 (en) | 2011-05-09 | 2012-11-15 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
US10155950B2 (en) * | 2014-02-28 | 2018-12-18 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
EP3374500A1 (en) * | 2015-11-13 | 2018-09-19 | Mammedov, Tarlan | Production of in vivo n-deglycosylated recombinant proteins by co-expression with endo h |
DK3184642T3 (en) * | 2015-12-22 | 2019-08-12 | Bisy E U | yeast |
WO2018055535A2 (en) | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004385A2 (en) * | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
WO1999054735A1 (en) * | 1998-04-17 | 1999-10-28 | Innogenetics N.V. | Improved immunodiagnostic assays using reducing agents |
WO1999067285A1 (en) * | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Particles of hcv envelope proteins: use for vaccination |
WO2001030815A1 (en) * | 1999-10-27 | 2001-05-03 | Innogenetics N.V. | Redox reversible hcv proteins with native-like conformation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4395395A (en) * | 1979-05-21 | 1983-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of non-A, non-B hepatitis associated antigen |
EP0288198A3 (en) | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production of peptide |
US5135854A (en) * | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
US5683864A (en) * | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
JP2791418B2 (en) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | Method for producing heterologous protein, recombinant DNA, transformant |
NO177065C (en) * | 1988-09-26 | 1995-07-12 | Labofina Sa | Process for the preparation of enzymatically active human lysozyme |
US5747239A (en) * | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
US6312889B1 (en) * | 1990-04-04 | 2001-11-06 | Chiron Corporation | Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
WO1992001800A1 (en) * | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
CA2047792C (en) | 1990-07-26 | 2002-07-02 | Chang Y. Wang | Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
HU227547B1 (en) | 1991-06-24 | 2011-08-29 | Novartis Vaccines & Diagnostic | Hepatitis c virus (hcv) polypeptides |
AU4659993A (en) | 1992-07-07 | 1994-01-31 | Merck & Co., Inc. | Vaccine comprising mixed pres1+pres2+s and core particle |
EP0979867A3 (en) | 1993-11-04 | 2007-06-13 | Innogenetics N.V. | Immunodominant human T-cell epitopes of hepatitis C virus |
ZA9610456B (en) * | 1995-12-20 | 1997-06-20 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
WO1998028429A1 (en) * | 1996-12-20 | 1998-07-02 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
WO1999024466A2 (en) | 1997-11-06 | 1999-05-20 | Innogenetics N.V. | Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes |
EP1049790A1 (en) * | 1998-01-23 | 2000-11-08 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
MXPA02008886A (en) | 2001-01-11 | 2003-04-25 | Innogenetics Nv | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use. |
EP1414942A2 (en) * | 2001-04-24 | 2004-05-06 | Innogenetics N.V. | Expression of core-glycosylated hcv envelope proteins in yeast |
JP2005516939A (en) | 2001-12-18 | 2005-06-09 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Purified hepatitis C virus coat protein for diagnostic and therapeutic uses |
CA2504711A1 (en) * | 2002-11-08 | 2004-05-21 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
-
2002
- 2002-04-24 EP EP02721875A patent/EP1414942A2/en not_active Withdrawn
- 2002-04-24 AR ARP020101495A patent/AR035869A1/en unknown
- 2002-04-24 JP JP2002583615A patent/JP4261195B2/en not_active Expired - Fee Related
- 2002-04-24 SK SK1314-2003A patent/SK13142003A3/en unknown
- 2002-04-24 CN CNA028126076A patent/CN1636050A/en active Pending
- 2002-04-24 NZ NZ529324A patent/NZ529324A/en unknown
- 2002-04-24 NZ NZ529019A patent/NZ529019A/en unknown
- 2002-04-24 RU RU2003130955/13A patent/RU2274643C2/en not_active IP Right Cessation
- 2002-04-24 AR ARP020101493A patent/AR035867A1/en unknown
- 2002-04-24 CA CA002443781A patent/CA2443781A1/en not_active Abandoned
- 2002-04-24 EP EP02727059A patent/EP1417298A2/en not_active Withdrawn
- 2002-04-24 MX MXPA03009626A patent/MXPA03009626A/en not_active Application Discontinuation
- 2002-04-24 CA CA002443740A patent/CA2443740A1/en not_active Abandoned
- 2002-04-24 CZ CZ20032853A patent/CZ20032853A3/en unknown
- 2002-04-24 US US10/128,590 patent/US7238356B2/en not_active Expired - Fee Related
- 2002-04-24 WO PCT/BE2002/000063 patent/WO2002086100A2/en active Application Filing
- 2002-04-24 HU HU0303924A patent/HUP0303924A2/en unknown
- 2002-04-24 OA OA1200500194A patent/OA13092A/en unknown
- 2002-04-24 PL PL02366621A patent/PL366621A1/en not_active Application Discontinuation
- 2002-04-24 BR BR0209034-1A patent/BR0209034A/en not_active IP Right Cessation
- 2002-04-24 MX MXPA03009632A patent/MXPA03009632A/en not_active Application Discontinuation
- 2002-04-24 AR ARP020101494A patent/AR035868A1/en unknown
- 2002-04-24 BR BR0209033-3A patent/BR0209033A/en not_active IP Right Cessation
- 2002-04-24 KR KR1020037013778A patent/KR100950104B1/en not_active IP Right Cessation
- 2002-04-24 AU AU2002308449A patent/AU2002308449B2/en not_active Ceased
- 2002-04-24 US US10/128,578 patent/US7048930B2/en not_active Expired - Fee Related
- 2002-04-24 WO PCT/BE2002/000062 patent/WO2002085932A2/en active IP Right Grant
- 2002-04-24 WO PCT/BE2002/000064 patent/WO2002086101A2/en active IP Right Grant
- 2002-04-24 AU AU2002257392A patent/AU2002257392B2/en not_active Ceased
- 2002-04-24 EP EP02764023A patent/EP1381671A2/en not_active Withdrawn
- 2002-04-24 YU YU84103A patent/YU84103A/en unknown
- 2002-04-24 JP JP2002583616A patent/JP4173741B2/en not_active Expired - Fee Related
- 2002-04-24 US US10/128,587 patent/US7314925B2/en not_active Expired - Fee Related
- 2002-04-24 CA CA002444006A patent/CA2444006A1/en not_active Abandoned
- 2002-04-24 AU AU2002252856A patent/AU2002252856A1/en not_active Abandoned
-
2003
- 2003-10-23 ZA ZA200308272A patent/ZA200308272B/en unknown
- 2003-10-23 ZA ZA200308277A patent/ZA200308277B/en unknown
- 2003-10-23 ZA ZA200308274A patent/ZA200308274B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004385A2 (en) * | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
WO1999054735A1 (en) * | 1998-04-17 | 1999-10-28 | Innogenetics N.V. | Improved immunodiagnostic assays using reducing agents |
WO1999067285A1 (en) * | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Particles of hcv envelope proteins: use for vaccination |
WO2001030815A1 (en) * | 1999-10-27 | 2001-05-03 | Innogenetics N.V. | Redox reversible hcv proteins with native-like conformation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002086100A3 (en) | Expression of core-glycosylated hcv envelope proteins in yeast | |
DK1261360T3 (en) | Casein-derived peptides and uses thereof in treatment | |
NO973627L (en) | Multifunctional enzyme | |
DE69922958D1 (en) | HCV HULL PROTEINS PARTICLES: USE FOR THERAPEUTIC VACCINATION | |
NO20052136L (en) | Hepatitis C virus (HCV) vaccine. | |
ATE234108T1 (en) | THERAPEUTIC FOR SUPPRESSING SNORING NOISES | |
EP2077324A3 (en) | Genes encoding proteolytic enzymes from aspargilli | |
WO2004085633A8 (en) | A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof | |
WO2003051912A3 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
ATE355375T1 (en) | BACTERIOFERRITIN FROM HELICOBACTER PYLORI | |
WO2003057856A3 (en) | Dominant negative proteins and methods thereof | |
EP1613345A4 (en) | Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 | |
ATA3552000A (en) | XYLOSYL TRANSFERASE GENE | |
WO2004070002A3 (en) | Cell lines and host nucleic acid sequences related to infectious disease | |
WO2003018606A3 (en) | Casein derived peptides and uses thereof in therapy | |
WO2000027880A3 (en) | Rantes-derived peptides with anti-hiv activity | |
WO2003037265A3 (en) | Method of treating viral infections | |
WO2004041853A3 (en) | Hcv vaccine compositions comprising e1 and ns3 peptides | |
WO2002055548A8 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
WO2004018002A3 (en) | Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells | |
DE60224280D1 (en) | USE OF OXYTOCIN FRAGMENTS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR EFFECTIVENESS OF EUSTASIS | |
WO2004006843A3 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
WO2004067024A3 (en) | Hcv combination therapy | |
DK1250422T3 (en) | Myeloid colony-stimulating factor and uses thereof | |
WO2004108756A3 (en) | Sars coronavirus peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2444006 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/08272 Country of ref document: ZA Ref document number: 200308272 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002583615 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002721875 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002721875 Country of ref document: EP |